Seliciclib Shows Promise in Treating Nasopharyngeal Carcinoma

Clinical trials involving seliciclib, a cyclin-dependent kinase (CDK) inhibitor, have shown promise in treating nasopharyngeal carcinoma, a type of cancer that affects the upper respiratory tract. Researchers at the National University in Singapore conducted a study to evaluate the pharmacodynamic effects of seliciclib in patients with nasopharyngeal carcinoma. The results of the study indicate that brief treatment with seliciclib at a dosage of 400 mg twice daily is tolerable and associated with tumor pharmacodynamic changes consistent with CDK inhibition.

Key Takeaways:

• The study involved 14 patients with treatment-naive locally advanced nasopharyngeal carcinoma who received seliciclib at either 800 mg or 400 mg twice daily for 3 days.
• Paired tumor samples were assessed using light microscopy, immunohistochemistry, and real-time PCR low-density array to evaluate changes in gene expression related to cell cycle inhibition, apoptosis, and cell proliferation.
• Seven out of 14 evaluable patients showed clinical evidence of tumor reduction, which was associated with increased tumor apoptosis, necrosis, and decreases in plasma EBV DNA post-treatment.
• Selective reduction in protein expression of Mcl-1, cyclin D1, and phosphorylated retinoblastoma protein pRB (T821) was observed in some patients post-treatment, indicating modulation of the cell cycle by seliciclib.
• The study's findings suggest that brief treatment with seliciclib in patients with nasopharyngeal carcinoma is tolerable and warrants further efficacy studies.

Statistics:

• 14 patients were evaluable in the study, with 7 showing clinical evidence of tumor reduction.
• 13 patients experienced no significant toxicities when treated with seliciclib at 400 mg twice daily.

Sources:

• Hsieh, W.S., et al. (2009). Pharmacodynamic Effects of Seliciclib, an Orally Administered Cell Cycle Modulator, in Undifferentiated Nasopharyngeal Cancer. Clinical Cancer Research, 15(4), 1435-1442.
• National University (Singapore)
• Nasopharyngeal Carcinoma.